Idiopathic short stature: a clinical review

Abstract

Importance: Approximately 2% of children are defined as having short stature. Deciding when to pursue recombinant human growth hormone therapy to increase adult height is controversial.

Objective: To review the management of children with idiopathic short stature, including diagnostic evaluation and therapeutic options.

Evidence review: Systematic literature search of PubMed, Embase, and the Cochrane Library databases. For height outcome, articles were limited to studies reporting adult height and to systematic reviews.

Findings: Recombinant human growth hormone therapy of children with idiopathic short stature increases height in some children. The estimated mean gain in adult height is 5.2 cm (2 in). The cost-benefit ratio is controversial. Treatment with growth hormone appears safe in the short term, while data on long-term effects are limited because studies of long-term efficacy were not powered to determine safety.

Conclusions and relevance: Growth hormone treatment may be considered in some children with idiopathic short stature.